The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies

• Published in: BMC genomics Vol. 4; no. 1; p. 13
• Main Authors: McCarty, Catherine A, Chisholm, Rex L, Chute, Christopher G, Kullo, Iftikhar J, Jarvik, Gail P, Larson, Eric B, Li, Rongling, Masys, Daniel R, Ritchie, Marylyn D, Roden, Dan M, Struewing, Jeffery P, Wolf, Wendy A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26-01-2011; BioMed Central; BMC
• Subjects: Administrative support; Algorithms; American Recovery and Reinvestment Act; Clinical Trials as Topic - methods; Correspondence; Diabetes Mellitus, Type 2 - genetics; Electronic Health Records; Electronic records; Ethical aspects; Genetic research; Genetic variation; Genetics; Genome; Genome-Wide Association Study; Genomes; Genomics; Genotype; Humans; Hypertension - genetics; Medical research; Medicine; National Human Genome Research Institute (U.S.); Peripheral Arterial Disease - genetics; Personal health; Population Groups; Science; Social aspects; Technology application; United States; United States; Australia
• ISSN: 1755-8794; 1471-2164; 1755-8794; 1471-2164
• DOI: 10.1186/1755-8794-4-13

The eMERGE (electronic MEdical Records and GEnomics) Network is an NHGRI-supported consortium of five institutions to explore the utility of DNA repositories coupled to Electronic Medical Record (EMR) systems for advancing discovery in genome science. eMERGE also includes a special emphasis on the ethical, legal and social issues related to these endeavors.
The five sites are supported by an Administrative Coordinating Center. Setting of network goals is initiated by working groups: (1) Genomics, (2) Informatics, and (3) Consent & Community Consultation, which also includes active participation by investigators outside the eMERGE funded sites, and (4) Return of Results Oversight Committee. The Steering Committee, comprised of site PIs and representatives and NHGRI staff, meet three times per year, once per year with the External Scientific Panel.
The primary site-specific phenotypes for which samples have undergone genome-wide association study (GWAS) genotyping are cataract and HDL, dementia, electrocardiographic QRS duration, peripheral arterial disease, and type 2 diabetes. A GWAS is also being undertaken for resistant hypertension in ≈ 2,000 additional samples identified across the network sites, to be added to data available for samples already genotyped. Funded by ARRA supplements, secondary phenotypes have been added at all sites to leverage the genotyping data, and hypothyroidism is being analyzed as a cross-network phenotype. Results are being posted in dbGaP. Other key eMERGE activities include evaluation of the issues associated with cross-site deployment of common algorithms to identify cases and controls in EMRs, data privacy of genomic and clinically-derived data, developing approaches for large-scale meta-analysis of GWAS data across five sites, and a community consultation and consent initiative at each site.
Plans are underway to expand the network in diversity of populations and incorporation of GWAS findings into clinical care.
By combining advanced clinical informatics, genome science, and community consultation, eMERGE represents a first step in the development of data-driven approaches to incorporate genomic information into routine healthcare delivery.